Investigating how certain chemicals damage DNA and lead to cancer
Studies of Chemically Labile Alkylation Damage in DNA
This study is looking at how certain chemicals can damage DNA in ways that might lead to cancer, and it aims to help patients understand how these changes happen and how they can be repaired, which could improve cancer treatments and awareness of environmental risks.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas at Austin NIH-funded |
| Lab location | 1 site (Austin, United States) |
| Project ID | NIH-11101370 on NIH RePORTER |
What this research studies
This research focuses on understanding how alkylating agents, which are chemicals that can attach to DNA, cause damage that may lead to mutations and cancer. The study specifically examines a type of DNA damage known as N7-alkylguanine adducts, which can interfere with DNA replication and transcription. By developing new technologies to analyze these lesions, the research aims to uncover the mechanisms behind their formation and repair, providing insights into cancer development. Patients may benefit from improved understanding of how certain cancer treatments and environmental exposures can affect their DNA.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals exposed to alkylating agents or those with a family history of cancers related to DNA damage.
Not a fit: Patients who do not have a history of exposure to alkylating agents or related cancers may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to better strategies for preventing and treating cancers caused by DNA damage.
How similar studies have performed: Previous research has shown success in understanding DNA damage mechanisms, but this specific approach using 2’-fluorine technology is relatively novel.
Where this research is happening
Austin, United States
- University of Texas at Austin — Austin, United States (Active)
Researchers
- Principal investigator: Lee, Seongmin — University of Texas at Austin
- Study coordinator: Lee, Seongmin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.